Department of Cardiac Surgery, Cardiocentro Ticino, Lugano, Switzerland.
Department of Surgery, New York Presbyterian Hospital, Columbia University, New York, NY.
J Thorac Cardiovasc Surg. 2022 Jan;163(1):94-105.e15. doi: 10.1016/j.jtcvs.2020.04.010. Epub 2020 Apr 15.
The optimal revascularization strategy for patients with left main coronary artery disease is still controversial. This is systematic review and meta-analysis aims to evaluate the outcomes of percutaneous coronary intervention (PCI) with drug-eluting stents compared with coronary artery bypass graft (CABG) for LM disease.
Online electronic databases were systematically reviewed until January 2020 for randomized trials comparing PCI with drug-eluting stents and CABG. Primary outcomes were: all-cause mortality, myocardial infarction (MI), stroke, and repeated revascularization. Secondary outcomes included periprocedural and nonperiprocedural MI. The period of follow-up included 30 days, 1 year, and 5 years. Odds ratio and 95% confidence interval were calculated with a fixed-effects model.
A total of 4595 patients (5 randomized trials) with left main coronary artery disease were included. At 30 days and 1 year, PCI was associated with lower incidence of stroke, higher repeated revascularization, and similar odds of mortality and MI compared with CABG. At 5 years, PCI was associated with higher rates of MI (odds ratio, 1.43; 95% confidence interval, 1.13-1.79; P = .003) and repeat revascularization (odds ratio, 1.89; 95% CI, 1.58-2.26; P < .001) than CABG. PCI was associated with lower periprocedural MI at 30 days, whereas at 5 years PCI was associated with higher nonperiprocedural MI (odds ratio, 2.32; 95% confidence interval, 1.62-3.31; P < .001). Mortality and stroke rate did not differ at 5-year follow-up.
Patients with left main coronary artery disease treated with either PCI or CABG do not show significant difference in early or 5-year mortality. Although CABG was associated with higher stroke rates at 30 days and 1 year, PCI was associated with an increase in MI and need for repeat revascularization at 5 years.
左主干冠状动脉疾病患者的最佳血运重建策略仍存在争议。本系统评价和荟萃分析旨在评估药物洗脱支架经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术(CABG)治疗左主干疾病的疗效。
系统检索在线电子数据库,截至 2020 年 1 月,比较 PCI 与药物洗脱支架和 CABG 治疗左主干疾病的随机试验。主要结局为全因死亡率、心肌梗死(MI)、卒中和再次血运重建。次要结局包括围术期和非围术期 MI。随访时间包括 30 天、1 年和 5 年。采用固定效应模型计算比值比和 95%置信区间。
共纳入 4595 例左主干冠状动脉疾病患者(5 项随机试验)。在 30 天和 1 年时,与 CABG 相比,PCI 组卒中发生率较低,再次血运重建率较高,死亡率和 MI 发生率相似。在 5 年时,PCI 组 MI(比值比,1.43;95%置信区间,1.13-1.79;P =.003)和再次血运重建(比值比,1.89;95%置信区间,1.58-2.26;P <.001)发生率较高。PCI 组在 30 天的围术期 MI 发生率较低,而在 5 年时的非围术期 MI 发生率较高(比值比,2.32;95%置信区间,1.62-3.31;P <.001)。5 年时的死亡率和卒中发生率无差异。
左主干冠状动脉疾病患者接受 PCI 或 CABG 治疗,在早期或 5 年死亡率方面无显著差异。虽然 CABG 在 30 天和 1 年时卒中发生率较高,但 PCI 组在 5 年时 MI 发生率增加且需要再次血运重建。